GlassScriptPhysician profile
Brent E Murchie
NPI 1831400027
$6,561.74
in general payments reported to CMS, 2019-2025
36 companies · $1,092 in 2025
The $1,092 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2020: $530 · 2021: $1,120 · 2022: $1,303 · 2023: $1,203 · 2024: $567 · 2025: $1,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,861.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,985.89 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $385.64 | 2019-2024 | Xifaxan |
| Pfizer INC. | $339.55 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $318.63 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $315.12 | 2019-2025 | Tremfya |
| Genzyme Corporation | $191.47 | 2023-2025 | |
| Celgene Corporation | $166.55 | 2022-2024 | Zeposia |
| Boston Scientific Corporation | $165.68 | 2019-2024 | Autocap Rx, Watchman Access System |
| Ardelyx, INC. | $159.02 | 2023-2025 | Ibsrela |
| Axonics, INC. | $150.58 | 2023 | Axonics |
| Nestle Healthcare Nutrition INC. | $144.77 | 2021-2023 | |
| Medtronic, INC. | $121.18 | 2022 | |
| Aimmune Therapeutics, INC. | $98.79 | 2025 | Vowst, Zenpep |
| Lilly USA, LLC | $98.56 | 2023-2025 | Omvoh |
| Fujifilm Healthcare Americas Corporation | $98.30 | 2023 | Fujifilm |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $84.80 | 2020-2024 | Ocaliva |
| Redhill Biopharma INC. | $76.85 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $76.57 | 2020-2023 | Dificid, Zinplava |
| Fresenius Kabi USA, LLC | $74.20 | 2023-2024 | Idacio |
| Madrigal Pharmaceuticals | $73.38 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $65.36 | 2019-2024 | Suflave, Sutab |
| Allergan, INC. | $59.36 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $44.00 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $35.56 | 2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $34.83 | 2020 | |
| Celltrion USA INC. | $22.34 | 2025 | Vegzelma |
| Ucb, INC. | $22.07 | 2022 | |
| Shionogi INC | $20.59 | 2019 | |
| Vivus LLC | $18.47 | 2021 | |
| Gilead Sciences, INC. | $18.33 | 2021 | |
| Sandoz INC. | $17.91 | 2025 | Hyrimoz |
| Organon LLC | $17.57 | 2023 | Hadlima |
| E.R. Squibb & Sons, L.L.C. | $16.30 | 2022 | |
| Ferring Pharmaceuticals INC. | $16.05 | 2023 | Rebyota |
| Lucid Diagnostics INC. | $14.56 | 2023 | |
| Conmed Corporation | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Murchie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.